Citigroup’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-181
| Closed | -$353 | – | 5962 |
|
|
2023
Q4 | $353 | Hold |
181
| – | – | ﹤0.01% | 5513 |
|
|
2023
Q3 | $436 | Hold |
181
| – | – | ﹤0.01% | 5227 |
|
|
2023
Q2 | $534 | Sell |
181
-1
| -0.5% | -$5 | ﹤0.01% | 5373 |
|
|
2023
Q1 | $2.04K | Sell |
182
-2
| -1% | -$26 | ﹤0.01% | 5087 |
|
|
2022
Q4 | $2.08K | Buy |
184
+2
| +1% | +$23 | ﹤0.01% | 5226 |
|
|
2022
Q3 | $3K | Sell |
182
-989
| -84% | -$24.3K | ﹤0.01% | 5448 |
|
|
2022
Q2 | $68K | Buy |
1,171
+1,159
| +9,658% | +$168K | ﹤0.01% | 4404 |
|
|
2022
Q1 | $5K | Buy |
12
+8
| +200% | +$5.11K | ﹤0.01% | 5861 |
|
|
2021
Q4 | $4K | Hold |
4
| – | – | ﹤0.01% | 5700 |
|
|
2021
Q3 | $7K | Hold |
4
| – | – | ﹤0.01% | 5560 |
|
|
2021
Q2 | $10K | Sell |
4
-2
| -33% | -$6.59K | ﹤0.01% | 5684 |
|
|
2021
Q1 | $25K | Sell |
6
-4
| -40% | -$21.6K | ﹤0.01% | 5122 |
|
|
2020
Q4 | $58K | Sell |
10
-2
| -17% | -$11.8K | ﹤0.01% | 5938 |
|
|
2020
Q3 | $73K | Sell |
12
-3
| -20% | -$17.2K | ﹤0.01% | 5342 |
|
|
2020
Q2 | $83K | Sell |
15
-2
| -12% | -$10.4K | ﹤0.01% | 5732 |
|
|
2020
Q1 | $62K | Buy |
+17
| New | +$97.6K | ﹤0.01% | 5778 |
|
|
2017
Q2 | – | Sell |
-1
| Closed | -$5K | – | 7538 |
|
|
2017
Q1 | $5K | Sell |
1
-1
| -50% | -$5.03K | ﹤0.01% | 6814 |
|
|
2016
Q4 | $20K | Buy |
+2
| New | +$28K | ﹤0.01% | 6534 |
|
|
2016
Q2 | – | Sell |
-5
| Closed | -$58K | – | 7549 |
|
|
2016
Q1 | $58K | Buy |
+5
| New | +$64.6K | ﹤0.01% | 6038 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 7301 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6854 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 7367 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 7508 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 7387 |
|
Other funds holding AGRX
Citigroup's AGRX Position: Q1 2024 in Review
Citigroup sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 181 shares — an estimated $353 sold.
Citigroup first reported a position in AGRX in Q1 2016 and held it in 19 quarters. The position peaked at $83K in Q2 2020. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.
- Citigroup reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
- Citigroup sold 181 Agile Therapeutics shares in Q1 2024, an estimated $353.
- Citigroup first reported a position in Agile Therapeutics in Q1 2016 and held it in 19 quarters.
- Citigroup's Agile Therapeutics position peaked at $83K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.
Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.